Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 5,496 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Completed Phase 2Phase 3 Interventional

Vitamin D Supplementation in HIV

NCT01475890
View directory record Official record
Conditions
HIV-infection/Aids
Interventions
Vitamin D3, Placebo
Dietary Supplement
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 24 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 14, 2026, 12:45 PM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

NCT04606576
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, ORMD-0801 QD, ORMD-0801 BD
Other · Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Mania Symptoms With Drug Therapy

NCT00183443
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Divalproex-extended release (DVP-ER), Lithium, Quetiapine
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 14, 2026, 12:45 PM EDT
Terminated Phase 2 Interventional Results available

Study of ASN51 in Adults With Early Alzheimer's Disease

NCT06677203
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ASN51, Placebo
Drug
Lead sponsor
Asceneuron S.A.
Industry
Eligibility
50 Years to 80 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Clermont, Florida • Lady Lake, Florida • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

NCT02757105
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
BEKINDA, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Huntsville, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients

NCT01197794
View directory record Official record
Conditions
Asthma Patients
Interventions
AZD1981, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Fullerton, California • Los Angeles, California • Mission Viejo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 14, 2026, 12:45 PM EDT
Not listed Phase 2 Interventional

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

NCT04822961
View directory record Official record
Conditions
mCRPC
Interventions
Placebo, Senaparib
Drug
Lead sponsor
Impact Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 14, 2026, 12:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Shatavari Root Extract in Women's Sexual Wellness

NCT07441083
View directory record Official record
Conditions
Sexual Wellness, Women Health
Interventions
Shatavari (Asparagus racemosus) Root Extract, Placebo Capsule
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
20 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 14, 2026, 12:45 PM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

NCT07664553
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Elecoglipron, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen

NCT00640627
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

NCT04583956
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Risankizumab
Other · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
32
States / cities
Tucson, Arizona • Bakersfield, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

NCT01054729
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir, Placebo, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

NCT00658086
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01, normal saline
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00877383
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
116
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT02397694
View directory record Official record
Conditions
HIV-1 Infection
Interventions
BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis

NCT00750139
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
NAFT-500, Placebo 2-weeks, Naftin 1%, Placebo 4-weeks
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2Phase 3 Interventional

AMX0035 and Progressive Supranuclear Palsy

NCT06122662
View directory record Official record
Conditions
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 14, 2026, 12:45 PM EDT
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 14, 2026, 12:45 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).

NCT01021423
View directory record Official record
Conditions
Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Lenalidomide, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

NCT01890746
View directory record Official record
Conditions
Acute Leukaemia
Interventions
Daunorubicin, Cytarabine, Eltrombopag, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
14
States / cities
Farmington, Connecticut • Miami, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 14, 2026, 12:45 PM EDT
Recruiting Phase 2Phase 3 Interventional

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673
View directory record Official record
Conditions
Alzheimer's Disease Psychosis
Interventions
ACP-204, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
50
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT01661673
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
EVP-0962, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
45 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 4 Interventional Results available

Nitrofurantoin Prophylaxis During Catheter-managed Acute Urinary Retention After Pelvic Reconstructive Surgery

NCT02727322
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Nitrofurantoin, Placebo
Drug
Lead sponsor
Halina M Zyczynski, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 14, 2026, 12:45 PM EDT
Not listed Phase 2 Interventional

Study of NSI-189 for Major Depressive Disorder

NCT02695472
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
80 Milligrams NSI-189, Placebo, 40 Milligrams NSI-189
Drug
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Garden Grove, California • National City, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 14, 2026, 12:45 PM EDT